Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

ClinicalTrials.gov ID: NCT01824303

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01824303. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purposes of the study is to determine if LiRIS®, an investigational drug-delivery system, is safe and tolerable in women with Interstitial Cystitis (IC), and to evaluate any change in IC symptoms following LiRIS administration.

Study identification

NCT ID: NCT01824303
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Allergan; Industry
Enrollment: 31 participants

Conditions and interventions

Conditions

Interstitial Cystitis

Interventions

LiRIS 400 mg Drug
LiRIS Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 2013 (Type not available)
Primary completion: Nov 2014 (Actual)
Completion: Dec 2014 (Actual)
Last update posted: Jan 26, 2016

2013 – 2014

United States locations

U.S. sites: 15
U.S. states: 9
U.S. cities: 15

Facility	City	State	ZIP	Site status
Citrus Valley Medical Research , Inc.	Glendora	California	91741	—
Atlantic Urological Associates	Daytona Beach	Florida	32114	—
University of Kansas Medical Center	Kansas City	Kansas	66160	—
The UrogynecologyCenter, LLC	Overland Park	Kansas	66209-2002	—
Female Pelvic Medicine & Urogynecology Institute of MI	Grand Rapids	Michigan	49503	—
William Beaumont Hospitals	Royal Oak	Michigan	48073	—
North Shore - Long Island Jewish Heath System - Monter Cancer Center	New Hyde Park	New York	11040	—
Premier Medical Group of the Hudson Valley PC	Newburgh	New York	12550	—
Premier Medical Group of the Hudson Valley PC	Poughkeepsie	New York	12601	—
Alliance Urology Specialists, PA	Greensboro	North Carolina	27403	—
Wake Forest Baptist Health	Winston-Salem	North Carolina	27103	—
MetroHealth Medical Center	Cleveland	Ohio	44109	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
Carolina Urologic Research Center	Myrtle Beach	South Carolina	29572	—
Volunteer Research Group, University of Tennessee Medical Center	Knoxville	Tennessee	37920	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01824303, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 26, 2016 · Synced Nov 14, 2026